Introduction
Significant progress in the treatment of human immunodeficiency virus type 1 (HIV-1) infection has been achieved by the advent of highly active antiretroviral therapy (HAART), which targets different steps in the viral replication cycle with multiple inhibitors (Yeni et al., 2004) . At present, one entry inhibitor, eight nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), three non-NRTIs (NNRTIs) and eight protease inhibitors (PIs) are available for the treatment of HIV-1 infection. HAART with these inhibitors has significantly decreased plasma viraemia to undetectable levels and has considerably improved the survival of infected individuals (Pomerantz & Horn, 2003) . However, considering the drug resistance and side effects of long-term HAART, discovery of novel HIV-1 agents with different mechanisms of action is still highly desirable. In addition, the reservoir cells containing latent HIV-1 are capable of producing infectious particles after cellular activation, which leads to a rebound of the viral load after interruption of HAART (Pierson et al., 2000) . Therefore, HAART cannot be terminated unless such reservoir cells have been eradicated or viral recovery from the cells can be completely suppressed. In this regard, inhibitors that selectively prevent HIV-1 gene expression can potentially inhibit the recovery of latent virus from resting memory T cells as well as infected monocytes/macrophages (M/Ms), which are also considered to be a long-surviving chronically infected cell population in HIV-1-infected patients.
Molecular analyses of HIV-1 replication have revealed a concerted complexity that regulates the viral life cycle. Among the various steps of the HIV-1 life cycle, transcription from the integrated proviral DNA is considered to be a crucial step for viral replication, as amplification of the viral genetic information is attainable only through transcription (Cullen, 1991; Jones & Peterlin, 1994; Okamoto, 1995) . The viral-encoded transactivator protein Tat stimulates transcriptional elongation through its interaction with the transactivation response (TAR) RNA structure. Tat also interacts with cellular cofactors, such as positive transcription elongation factor b (P-TEFb), a complex composed of cyclin T1 and cyclin-dependent kinase 9 (CDK9; Peng et al., 1998; Price, 2000; Wei et al., 1998) . CDK9 hyperphosphorylates the carboxy-terminal domain of RNA polymerase II, and induces efficient promoter clearance and transcriptional elongation. In addition to the viral protein Tat, several cellular factors are known to regulate HIV-1 gene expression (Peterlin & Trono, 2003) . Among these factors, nuclear factor κB (NF-κB) is the most potent activator of HIV-1 gene expression (Nobel & Baltimore, 1987) . In general, NF-κB exists in an inactive form in the cytoplasm, where it is bound to the inhibitory molecule IκBα. Stimulation of the cells with several cytokines, such as tumour necrosis factor-α (TNFα), leads to the immediate degradation of IκBα and activates NF-κB, resulting in immediate translocation of NF-κB from the cytoplasm to the nucleus (Roulston et al., 1995) . HIV-1 gene expression is initiated and enhanced by the activation of NF-κB and subsequent binding to the specific DNA motifs in the enhancer region of the HIV-1 long terminal repeat (LTR). However, complex and unknown machinery may also be involved in the regulation of HIV-1 gene expression.
Several compounds have been reported to suppress HIV-1 gene expression and replication through the inhibition of Tat or NF-κB. In our previous studies, the fluoroquinoline derivative K-37 proved to be a potent and selective HIV-1 transcription inhibitor in both acutely and chronically infected cells at nanomolar concentrations (Baba et al., 1998) . K-37 was an inhibitor of not only Tat but also other RNA-dependent transactivators. Although its target molecule remains to be elucidated, the aminoquinolone WM5, which is structurally related to K-37, was found to interact with the bulge region of the TAR (Parolin et al., 2003; Richter et al., 2004) .
In our recent extensive search programme for novel HIV-1 transcription inhibitors, more than 100,000 compounds have been examined for their inhibitory effects on HIV-1 LTR-driven reporter gene expression in cell cultures. Among the test compounds, several compounds showed selective inhibition of HIV-1 replication in chronically infected cells; the novel naphthalene derivative JTK-101 ( Figure 1 ) was selected as the representative of the active compounds because it exhibited the highest selectivity. JTK-101 is a more potent and selective transcription inhibitor of HIV-1 than K-37 in latently and chronically infected cells. Studies of its mechanism of action suggest that JTK-101 is an inhibitor of Tat cofactors, presumably CDK9/cyclin T1. (Tokyo, Japan). Lamivudine (3TC), zidovudine (AZT), and the histone deacetylase inhibitor trichostatin A (TSA) were purchased from Sigma (St. Louis, MO, USA). All compounds were dissolved in DMSO at 10 mM or higher concentrations to exclude any antiviral or cytotoxic effect of DMSO and stored at -20°C until use.
Materials and methods

Cells and virus
Peripheral blood mononuclear cells (PBMCs), CEM, MOLT-4, OM-10.1 cells, MOLT-4/III B , and U937/III B cells were used in antiviral assays. OM-10.1 cells are a clone of HL-60 cells latently infected with HIV-1. MOLT-4/III B and U937/III B cells are MOLT-4 and U937 cells chronically infected with HIV-1 (III B strain), respectively. PBMCs were obtained from healthy donors and stimulated with phytohaemagglutinin (PHA; Sigma). W-3 and KM-3 cells were clones of CEM cells that stably integrate an HIV-1 LTR-driven secreted alkaline phosphatase (SEAP) gene. The integrated HIV-1 LTR contains two intact NF-κB-binding sites in W-3 cells, whereas both of the sites are mutated in KM-3 cells. M/Ms were isolated from healthy donors and cultivated according to the procedure described previously (Perno et al., 1988) . Two strains of HIV-1 (III B and Ba-L) were used in antiviral assays. III B and Ba-L are CXCR4-and CCR5-using strains, respectively. One CCR5-using HIV-1 isolate (CTV), and one CCR5-and CXCR4-using HIV-1 isolate (HE) were also used in antiviral assays.
Antiviral assays
The activities of the compounds against chronic HIV-1 infection were based on the inhibition of HIV-1 p24 antigen production. OM-10.1 cells (1×10 5 cells/ml) were incubated in the absence or presence of the compounds for 2 h and stimulated with 1 ng/ml TNF-α (Boehringer-Mannheim, Mannheim, Germany), whereas MOLT-4/III B and U937/III B cells (1×10 5 cells/ml) were cultured in the absence or presence of the test compounds without any stimulation. After 3 days of incubation at 37˚C, the culture supernatants were collected and their p24 antigen levels were determined with a sandwich enzyme-linked immunosorbent assay kit (Cellular Products, Buffalo, NY, USA). The cytotoxicity of the test compounds for the chronically infected cells were determined by the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (Pauwels et al., 1988) .
The assay procedure for measuring the anti-HIV-1 activity of the compounds in chronically infected M/Ms was also based on the quantitative detection of p24 antigen in the culture supernatants. The isolated M/Ms (5×10 4 cells/ml) were cultured in RPMI 1640 medium supplemented with 10% heat-activated fetal calf serum, 10% heat-inactivated human AB serum, penicillin G (100 U/ml), and streptomycin (100 μg/ml). At day 7, differentiated M/Ms were infected with HIV-1 Ba-L (10 ng of p24 per 5×10 4 cells). After 24 h incubation, the cells were washed and cultured for a further 9 days. After extensive washing, chronically infected M/Ms were cultured in the absence or presence of the test compounds for 4 days without medium change. The culture supernatants were collected and examined for their p24 antigen levels. The cytotoxicity of the test compounds for M/Ms was also determined by the MTT method.
The compounds' activities against acute HIV-1 infection were based on the inhibition of virus-induced cytopathicity in CEM cells and p24 antigen production in PBMCs, as described previously (Baba et al., 1998) . CEM cells (1×10 5 cells/ml) were infected with the virus at a multiplicity of infection of 0.01 and cultured in the presence of various concentrations of the compounds. After 4 days of incubation at 37˚C, the CEM cells were subcultured at a ratio of 1:5 with fresh culture medium containing appropriate concentrations of the test compounds and further cultured. For the assays in PBMCs, the cells (1×10 5 cells/ml) were infected with HIV-1 at a multiplicity of infection of 0.1. After virus adsorption for 2 h, the cells were extensively washed to remove unadsorbed virus particles and cultured in the presence of various concentrations of the test compounds. After 6 days incubation at 37˚C, the culture supernatants were collected and examined for their p24 antigen levels. The cytotoxicity of the test compounds were also determined by the MTT method.
Quantitative RT-PCR analysis OM-10.1 cells (2.5×10 5 cells/ml) were incubated in the absence or presence of the JTK-101 for 2 h, stimulated with 1 ng/ml TNF-α, and further incubated for 24 h. Total RNA was extracted from the cells with an RNA extraction kit (Promega, Madison, WI, USA). The extracted RNA was subjected to quantitative RT-PCR analysis to determine HIV-1 mRNA, using GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). For quantitative RT-PCR, Taqman One-Step RT-PCR Master Mix Reagents Kit (Applied Biosystems) was used according to the manufacturer's instructions. Using the sequence of the HIV-1 molecular clone HXB2, a primer pair and a probe were designed downstream of the transcription initiation site for HIV-1 mRNA. The primer pairs and the probes were 581F
(5′-TGGTAACTAGAGTCCCTCAGACC-3′, nucleotide position 582-605), 683R (5′-AGCTCCTCTG-GTTTCCCTTTC-3′, nucleotide position 662-682) and 620T (5′-TGGAAAATCTCTCTAGCAGTGGCGCC-GAAC-3′, nucleotide position 619-647). Non-specific inhibition of host cellular mRNA synthesis by JTK-101 was determined with Taqman GAPDH Control Reagents kit (Applied Biosystems).
Reporter gene assays
W-3 and KM-3 cells were either treated with 10 ng/ml TNF-α or transfected with 1 μg of plasmid expressing HIV-1 Tat, which contains the second exon under the control of the simian virus 40 promoter (modification of pSV2tat72), by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The cells were cultured in the presence of various concentrations of the test compounds. After 2 days of incubation at 37˚C, the SEAP activities in the culture supernatants were determined by chemiluminescence. The SEAP activities were measured using the GreatEscape SEAP detection kit (CLONTECH, Palo Alto, CA, USA), according to the manufacturer's instructions. The chemiluminescence intensity was measured with a LB96P luminometer (Berthold, Wildbad, Germany). At the same time, the number of viable cells was determined by the MTT method.
Immunoblot analysis
Immunoblot analysis was performed as described previously (Wang et al., 2002) . Briefly, cells extracts were prepared by incubating cells in lysis buffer (50 mM Tris [pH 8.0], 120 mM NaCl and 0.5% NP-40) containing protease inhibitor cocktail and phenylmethylsulphonyl fluoride (Sigma, St. Louis, MO, USA). Protein concentra-tions were determined by Bio-Rad protein assay, and equal amount of total protein was loaded onto 10% sodium dodecyl sulphate-polyacrylamide gels. The immunoblotting procedure using enhanced chemiluminescence for detection was also described previously. CDK9 was detected using a rabbit polyclonal antibody (C-20 sc-484; Santa Cruz Biotechnology, Santa Cruz, CA, USA), Cyclin T1 was detected using a goat polyclonal antibody (T-18 sc-8127; Santa Cruz Biotechnology), and actin was detected with goat polyclonal antibody (C-11 sc-1615; Santa Cruz Biotechnology). Complexes were then detected using an antirabbit horseradish peroxidase-conjugated secondary goat antibody and an anti-goat horseradish peroxidase-conjugated secondary rabbit antibody (MP Biomedicals, Aurora, OH, USA), and visualized by enhanced chemiluminescence western blotting detection system (Amersham Biosciences, Buckinghamshire, UK). For chronically infected M/Ms, the isolated M/Ms were kept uninfected or infected with HIV-1 Ba-L (10 ng of p24 per 5×10 4 cells). After chronic infection of M/Ms with HIV-1 Ba-L , the M/M cells and culture super-natants were collected on day 17 for cellular extract preparation and p24 antigen detection, respectively. HIV-1 p24 levels in four donors ranged between 30 and 200 ng/ml (data not shown). As a control, PBMCs obtained from the same donors and stimulated with PHA for 3 days were also used for western blot analysis for CDK9 and cyclin T1.
Results
Antiviral activity in chronically infected cell lines
We first evaluated JTK-101 for its inhibitory effects on HIV-1 replication in chronically infected cells. OM-10.1 cells produce little or no HIV-1 under basal conditions, but do produce a significant level of virus after stimulation with TNF-α or phorbol 12-myristate 13-acetate (PMA; Butera et al., 1991) . In fact, the level of HIV-1 p24 antigen in culture supernatant was less than 1 ng/ml in unstimulated OM-10.1 cells, yet it reached 100 ng/ml or more after stimulation with 1 ng/ml TNF-α (data not shown). As shown in Figure 2A , JTK-101 suppressed p24 antigen production in TNF-α-stimulated OM-10.1 cells in a dose-dependent fashion. The compound completely prevented p24 antigen production at a concentration of 0.08 μM. However, it did not reduce cell viability and proliferation at a concentration of 2 μM. The EC 50 and CC 50 of JTK-101 were 0.0014 and 3.8 μM, respectively. K-37 ( Figure 1) , another potent HIV-1 transcription inhibitor, could also suppress the production of p24 antigen in a dose-dependent fashion ( Figure 2B ). The EC 50 and CC 50 of K-37 was 0.033 and 2.1 μM, respectively (Table 1) . Thus, their selectivity indexes, based on the ratio of their CC 50 s to EC 50 s, were 2,714 and 63 for JTK-101 and K-37, respectively, indicating that JTK-101 is a much more potent and selective inhibitor of HIV-1 replication in chronically infected cells than K-37.
The inhibitory effects of JTK-101 on HIV-1 replication were also evaluated in MOLT-4/III B and U937/III B cells, both of which continuously produce a large amount of virus without any stimuli (data not shown). As shown in Figure  3A , JTK-101 efficiently suppressed HIV-1 production in MOLT-4/III B cells even at very low concentrations, yet higher concentrations are required to completely block viral production in MOLT-4/III B cells than in OM-10.1 cells. Again, K-37 was less active than JTK-101. The EC 50 s of JTK-101 and K-37 in MOLT-4/III B cells were 0.0057 and 0.074 μM, respectively (Table 1) . Interestingly, little, if any, suppression of HIV-1 production by JTK-101 was observed in U937/III B cells even at high concentrations ( Figure 3B ). In contrast, K-37 had similar inhibitory effect on HIV-1 production in MOLT-4/III B and U937/III B cells ( Figure 3C and 3D) . The NRTI 3TC was totally inactive in these chronically infected cells, such as OM-10.1 and MOLT-4/III B (Table 1) .
Antiviral activity in acutely infected cells
In the next experiment, JTK-101 was examined for its inhibition of HIV-1 (III B strain) replication in acutely infected CEM cells and PBMCs. Although JTK-101 could suppress p24 antigen production in culture supernatants at non-toxic concentrations, the compound was found to be less inhibitory to HIV-1 replication in acutely infected cells than in chronically infected cells (Tables 1  and 2 ). The EC 50 and CC 50 of JTK-101 for HIV-1 IIIB in CEM cells were 0.031 and 1.0 μM, respectively, and its EC 50 and CC 50 in PBMCs were 0.39 and 1.2 μM, respectively (Table 2) . Furthermore, JTK-101 also showed similar antiviral activity against the dual-tropic isolate HE and the R5 clinical isolate CTV in acutely infected MOLT-4 cells and PBMCs, respectively (data not shown). Unlike JTK-101, K-37 appeared to be equally inhibitory to HIV-1 replication in acutely and chronically infected cells (Tables  1 and 2) . AZT was a highly potent inhibitor of HIV-1 replication in acutely infected CEM cells.
Inhibitory effect on HIV-1 transcription
As JTK-101 was selected through screening in an HIV-1 LTR-driven reporter gene expression system and showed potent anti-HIV-1 activity in chronically infected cells, the compound was assumed to be an HIV-1 transcription inhibitor. Therefore, quantitative RT-PCR analysis was conducted to determine whether JTK-101 could prevent HIV-1 mRNA synthesis in TNF-α-stimulated OM-10.1 cells. As shown in Figure 4 , JTK-101 selectively suppressed TNF-α-induced HIV-1 mRNA synthesis in a dosedependent fashion. Even at a concentration of 1 nM, the compound could prevent HIV-1 mRNA synthesis by 60% in the cells. By contrast, it did not affect glyceraldehydes-3phosphate dehydrogenase (GAPDH) mRNA synthesis at concentrations up to 100 nM, indicating that JTK-101 selectively inhibits HIV-1 growth at the transcriptional level.
Inhibitory effects on TNF-α-and Tat-induced transactivation
To elucidate whether JTK-101 primarily inhibits Tat or the cellular transcriptional factor NF-κB, transfection experiments with a Tat expression plasmid into W-3 and KM-3 cells were conducted. Transfection with the Tat expression plasmid induced an increase of SEAP production in both W-3 and KM-3 cells. In contrast, treatment with TNF-α Table 1 . Inhibitory effects of JTK-101 and other selected compounds on HIV-1 replication in chronically infected cells* (10 ng/ml) induced an increase of SEAP production in W-3 cells, but not KM-3 cells, because two NF-κB binding sites of the HIV-1 LTR were mutated in KM-3 cells (Baba et al., 1999) . In both W-3 and KM-3 cells, JTK-101 could reduce the Tat-induced SEAP production in a dose-dependent fashion ( Figure 5A) . Interestingly, JTK-101 reduced the Tat-induced SEAP production more efficiently in KM-3 cells than in W-3 cells -its IC 50 values in W-3 and KM-3 cells were 110 and 4.5 nM, respectively. K-37 inhibited Tat-induced SEAP production less than JTK-101. However, there was no substantial difference between K-37's activity in W-3 and KM-3 cells. The IC 50 of K-37 in W-3 and KM-3 cells were 318 and 236 nM, respectively ( Figure 5B ). Furthermore, JTK-101 could reduce the TNF-α-induced SEAP production in W-3 cells with an IC 50 of 229 nM, whereas K-37 had no effect on the TNF-α-induced SEAP production ( Figure 5C and 5D ).
In both cell systems, the compounds did not affect basal SEAP production (data not shown). These results suggest that JTK-101 is capable of inhibiting both Tat-and NF-κB-triggered gene expressions. However, the compound seems to predominantly interfere with a Tat-associated mechanism rather than a NF-κB-associated one. Both JTK-101 and K-37 were found to efficiently inhibit PMAand TSA-induced HIV-1 production in OM-10.1 cells (data not shown).
CDK9/cyclin T1 level and JTK-101 activity
As the expression of CDK9 and cyclin T1 affect the transactivation by Tat, the protein levels of CDK9 and cyclin T1 were evaluated in several chronically infected cells. As shown in Figure 6 , CDK9 and cyclin T1 were highly expressed in the T-lymphoblastoid cell lines CEM and MOLT-4. However, only low levels of the molecules were detected in the promonocytic cell line U937. Chronic infection of MOLT-4 and U937 cells with HIV-1 did not significantly alter the expression of CDK9 and cyclin T1. Furthermore, like MOLT-4/III B cells, OM-10.1 cells displayed high level expression of CDK9 and cyclin T1. These results suggest that the poor activity of JTK-101 against HIV-1 production in U937/III B is partly attributed to the low level expression of CDK9 and cyclin T1. It was reported that the downregulation of cyclin T1 expression at a late stage of M/Ms differentiation contributed to low or absent Tat transactivation function at this stage (Liou et al., 2002) . Therefore, the level of CDK9 and cyclin T1 expression and the anti-HIV-1 activity of JTK-101 were examined in differentiated and chronically infected M/Ms. As expected, the expression of cyclin T1 was an undetectable level in both uninfected and chronically infected M/Ms after 17 days of cultivation ( Figure  7A ). CDK9 was also undetectable, although activated PBMCs obtained from the same donor displayed a high level of cyclin T1 and CDK9 expression. Furthermore, JTK-101 did not inhibit HIV-1 production in chronically infected M/Ms (Figure 7B) , whereas K-37 did inhibit HIV-1 production in a dose-dependent fashion (data not shown). These results suggest that the interaction of JTK-101 with either cyclin T1 or CDK9, or both, is needed to exert its anti-HIV-1 activity.
Discussion
The presence of reservoir cells that contain latent viruses results in the prodcution of infectious particles upon cellular activation, which leads to a rebound of the viral load after interruption of HAART (Pierson et al., 2000) . The persistence of these virus reservoirs, despite prolonged HAART treatments, represents a major obstacle to the eradication of HIV-1 in infected patients (Finzi et al., 1997; Wong et al., 1997) . Therefore, therapeutic targets for HIV-1 replication at the level of transcriptional activation hold great potential for further attempts at clearing viral latency. In this study, we have identified JTK-101, a novel naphthalene derivative, as a potent and selective transcription inhibitor of HIV-1 in latently and chronically infected cells. JTK-101 did not prevent proviral DNA synthesis (data not shown), suggesting that viral entry, uncoating, reverse transcription and integration are not the target of this compound. Furthermore, the inhibition of HIV-1 transcription by JTK-101 is potent and selective. Quantitative RT-PCR analysis revealed that JTK-101 almost completely inhibited HIV-1 mRNA synthesis without altering the level of GAPDH mRNA in TNF-α-treated OM-10.1 cells at a concentration of 100 nM (Figure 4) . K-37, an anti-HIV-1 fluoroquinoline derivative, also displayed selective inhibition of HIV-1 replication in acutely and chronically infected cells (Tables 1 and 2) . However, its antiviral activity was weaker than that of JTK-101. K-37 was capable of inhibiting RNA-dependent transactivation mediated by Tat, but did not inhibit DNA-dependent transactivation mediated by NF-κB (Baba et al., 1998; Okamoto et al., 2000) . Furthermore, K-37 did not inhibit but stimulated the NF-κB-mediated transactivation at the highest concentration tested (1,000 nM), yet the mechanism was still unknown ( Figure 5D ). Unlike K-37, JTK-101 could inhibit not only Tat but also NF-κB-mediated transactivation of the HIV-1 LTR ( Figure 5 ). Although JTK-101 was highly inhibitory to Tat-mediated transactivation, a much higher concentration was required to inhibit NF-κB-mediated transactivation. Thus, it is assumed that JTK-101 exerts its potent anti-HIV-1 activity primarily through the inhibition of Tat function rather than NF-κB. Furthermore, JTK-101 was still active against HIV-1 replication in OM-10.1 cells, even when added to culture medium 24 h after stimulation with TNF-α (data not shown). The compound showed a similar inhibitory effect on TSA-induced HIV-1 production in OM-10.1 cells (data not shown), further suggesting that NF-κB was not a major target. Although the cellular transcription factor NF-κB plays an important role in triggering HIV-1 gene expression, the activation of NF-κB leads to rapid production of Tat, which may be necessary to maintain continuous HIV-1 gene expression in latently infected cells. Therefore, as well as NF-κB inhibitors, a Tat inhibitor could be effective in restricting the recovery of latent virus from resting T cells in vivo. Stevens et al. (2007) recently reported that N-aminoimidazole derivatives interfered with viral replication at a post-integrational level by inhibiting HIV-1 mRNA transcription. However, A and B) , W-3 and KM-3 cells were transfected with the Tat expression plasmid (1 μg). For tumour necrosis factor (TNF)-α-induced transactivation (C and D), W-3 and KM-3 cells were treated with or without TNF-α (10 ng/ml). The cells were cultured in the presence of various concentrations of the compounds. After 2 days of incubation, the culture supernatants were collected and examined for their secreted alkaline phosphatase (SEAP) levels. At the same time, the number of viable cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) methods. Transfection with the Tat expression plasmid induced 8.8-and 6.3-fold increase of SEAP production in W-3 and KM-3 cells, respectively. While TNF-α stimulation induced 3.5-and 0.9-fold increases of SEAP production in W-3 and KM-3 cells, respectively. Effects of JTK-101 (A and C) and K-37 (B and D) on TNF-α-or HIV-1 Tat-induced transactivation were expressed as percent inhibition of SEAP activity. All experiments were carried out in duplicate and expressed as means (ranges).
Representative results for two independent experiments are shown.
A B C D unlike JTK-101, these compounds enhanced NF-κB binding at the HIV-1 promoter. Furthermore, they suppressed viral transcription via potent inhibitory effects on the recruitment of Tat to the HIV-1 promoter and on the transcriptional processivity of RNA polymerase II during the viral transcription process (Stevens et al., 2007) .
In spite of robust inhibition of HIV-1 replication in the chronically infected cells OM-10.1 and MOLT-4/III B , JTK-101 did not produce a significant inhibitory effect in U937/III B cells and primary M/Ms. It showed less inhibitory to HIV-1 replication in acutely infected cells, especially in acutely infected PBMCs, than in chronically infected cells This difference in anti-HIV-1 activity between acute and chronic stages of infection could be attributed to a distinct role of Tat in the infection stage or to the possibility that the compound interacts with known or unknown cellular factors involved in Tat-mediated transactivation.
Several lines of evidence have suggested that Tat function is largely dependent upon the interaction with the cellular transcription factor TAK/P-TEFb, a complex containing cyclin T1 and CDK9 (Herrmann & Rice, 1995; Mancebo et al., 1997) . In fact, several CDK inhibitors were found to potently suppress Tat functions and inhibited HIV-1 replication in cell cultures (Heredia et al., 2005; Wang et al., 2001) . Our preliminary experiments demonstrated that JTK-101 could inhibit CDK9 with an IC 50 of 0.3 μM, whereas it did not show any inhibition of CDK7 and casein kinase II (data not shown). Although direct interaction between JTK-101 and CDK9 has not been demonstrated, its activity was totally dependent on the expression of CDK9 and cyclin T1 in infected cells. The expression of TAK/P-TEFb, especially cyclin T1, was regulated during differentiation from monocytes to macrophages. PMA, vitamin D 3 and other agents cause the human myelomonocytic cell line HL-60 and the promonocytic cell line U937 to differentiate into terminal cells exhibiting macrophage characteristics, accompanied by a dramatic increase in their cyclin T1 levels (Herrmann et After 24 h incubation, the cells were washed and further incubated. On day 17, the cells were harvested for cell extracts preparation. Western blot analysis was performed, as described in Figure 6 . The culture supernatants were also collected on day 17 for p24 antigen detection. Their p24 levels of infected M/Ms on days 2 and 7 were 221.5 and 27.3 ng/ml, respectively. As a control, peripheral blood mononuclear cells (PBMCs) from same donors stimulated with phytohaemagglutinin (PHA) for 3 days were also examined (lane 1). (B) Inhibitory effects of JTK-101 on HIV-1 replication in chronically infected M/Ms. The isolated M/Ms were cultured for 7 days and infected with HIV-1 Ba-L . After 24 h of incubation, the cells were washed and cultured for further 9 days. After extensive washing, chronically infected M/Ms were cultured in the presence of various concentrations of JTK-101. After 4 days of incubation, the p24 antigen levels of culture supernatants (lines) were measured by ELISA. At the same time, the number of viable cell was determined by the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) method (columns). The experiments were repeated four times with PBMCs obtained from different donors; representative results are shown.
